MDER (Medera) Treasury Stock: $0.00 Mil (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Medera Treasury Stock?

Medera MDER Treasury Stock is $0.00 Mil as of Jun. 2024.

Treasury stock is the portion of shares that a company keeps in their own treasury. Medera's treasury stock for the quarter that ended in Jun. 2024 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Medera Treasury Stock Historical Data

* Premium members only.

The historical data trend for Medera's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medera Treasury Stock Chart

Medera Annual Data
Trend Dec22 Dec23
Treasury Stock
0.00 0.00

Medera Semi-Annual Data
Dec22 Jun23 Dec23 Jun24
Treasury Stock 0.00 0.00 0.00 0.00

Medera Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of $0.00 Mil mean?
Medera (MDER) has a Treasury Stock of $0.00 Mil as of Jun. 2024. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Medera and its competitors.
Is Medera's Treasury Stock too high?
Medera's current Treasury Stock is $0.00 Mil.
How does Medera's Treasury Stock compare to ?
Medera's Treasury Stock of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Biotechnology company?
A good Treasury Stock depends on the Biotechnology industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Medera and its competitors. Medera's current Treasury Stock is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medera stock overvalued right now?
Medera (MDER) has a current Treasury Stock of $0.00 Mil. The current Treasury Stock is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For Medera (MDER), the current Treasury Stock is $0.00 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medera Business Description

Comparable Companies
Address 6 Tide Street, 2nd Floor, Boston, MA, USA, 02210
Medera Inc is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates through two arms, namely: (1) pre-clinical disease modeling and drug discovery under Medera's Novoheart brand, which includes its bioengineered human mini-heart technology platform and related state-of-the-art technologies for preclinical screening; and (2) clinical development of novel therapies under Medera's Sardocor brand, which aspires to create the shortest regulatory path to clinic for advancing next-generation gene therapies (by leveraging the above Novoheart platform), in particular, for cardiovascular diseases.